A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE) in Combination With ZD6474 (ZACTIMA) Versus Docetaxel (TAXOTERE) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC
Phase 3
- Conditions
- on-Small Cell Lung Cancer, Lung Cancer
- Registration Number
- JPRN-jRCT2080220351
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Ages Eligible for Study: 18 Years and above
Genders Eligible for Study: Both
Inclusion Criteria:
- Confirmed locally advanced or metastatic NSCLC
- Failure of prior 1st line anti-cancer therapy
Exclusion Criteria
- Cancer other than NSCLC
- Prior treatment with docetaxel
- Prior 2nd line anti-cancer therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety/Efficacy
- Secondary Outcome Measures
Name Time Method